Literature DB >> 8322168

Effects of leflunomide on immune responses and models of inflammation.

R R Bartlett1, H Anagnostopulos, T Zielinski, T Mattar, R Schleyerbach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8322168     DOI： 10.1007/bf00192310

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  27 in total

Review 1.  Proteoglycan-specific autoreactive antibodies and T-lymphocytes in experimental arthritis and human rheumatoid joint diseases.

Authors:  T T Glant; C Fülöp; K Mikecz; E Buzás; G Molnár; P Erhardt
Journal:  Biochem Soc Trans       Date:  1990-10       Impact factor: 5.407

2.  IL-3-induced activation of protein kinases in the mast cell/megakaryocyte R6-XE.4 line.

Authors:  S L Pelech; H B Paddon; D L Charest; B S Federsppiel
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

3.  Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice.

Authors:  S Popovic; R R Bartlett
Journal:  Agents Actions       Date:  1986-12

Review 4.  Etiopathogenesis of murine SLE.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Immunol Rev       Date:  1981       Impact factor: 12.988

5.  Binding of G-CSF, GM-CSF, tumor necrosis factor-alpha, and gamma-interferon to cell surface receptors on human myeloid leukemia cells triggers rapid tyrosine and serine phosphorylation of a 75-Kd protein.

Authors:  J P Evans; A R Mire-Sluis; A V Hoffbrand; R G Wickremasinghe
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

6.  Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis.

Authors:  P Hambleton; S McMahon
Journal:  Agents Actions       Date:  1990-03

7.  Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease.

Authors:  R R Bartlett; S Popovic; R X Raiss
Journal:  Scand J Rheumatol Suppl       Date:  1988

8.  Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat.

Authors:  R R Bartlett; R Schleyerbach
Journal:  Int J Immunopharmacol       Date:  1985

9.  Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology.

Authors:  T T Glant; K Mikecz; A Arzoumanian; A R Poole
Journal:  Arthritis Rheum       Date:  1987-02

10.  A spontaneous rheumatoid arthritis-like disease in MRL/l mice.

Authors:  L Hang; A N Theofilopoulos; F J Dixon
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307
View more
  22 in total

1.  A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.

Authors:  L C Hamilton; I Vojnovic; T D Warner
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A.

Authors:  K Thoss; S Henzgen; P K Petrow; D Katenkamp; R Brauer
Journal:  Inflamm Res       Date:  1996-02       Impact factor: 4.575

3.  Leflunomide: Is It the Game Changer in Musculoskeletal Chronic Graft Versus Host Disease?

Authors:  Kalasekhar Vijaysekharan; Sachin Punatar; Avinash Bonda; Aniket Mohite; Kartthik Shanmugam; Lingaraj Nayak; Anant Gokarn; Navin Khattry
Journal:  Indian J Hematol Blood Transfus       Date:  2018-02-12       Impact factor: 0.900

4.  Hepatic damage in biliary-obstructed rats is ameliorated by leflunomide treatment.

Authors:  Abdurrahman Karaman; Mustafa Iraz; Hale Kirimlioglu; Nese Karadag; Erkan Tas; Ersin Fadillioglu
Journal:  Pediatr Surg Int       Date:  2006-08-05       Impact factor: 1.827

5.  Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice.

Authors:  Chunyan He; Xuehong Lu; Zhaowei Yan; Man Wu; Shujun Liu; Yongli Yu; Ping Luo
Journal:  Rheumatol Int       Date:  2010-12-03       Impact factor: 2.631

6.  Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.

Authors:  D L Scott; J S Smolen; J R Kalden; L B van de Putte; A Larsen; T K Kvien; M Schattenkirchner; P Nash; C Oed; I Loew-Friedrich
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

7.  Leflunomide: an active antiinflammatory and antiproliferative agent in models of dermatologic disease.

Authors:  E S Kurtz; S C Bailey; F Arshad; A A Lee; P A Przekop
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

Review 8.  Leflunomide: mode of action in the treatment of rheumatoid arthritis.

Authors:  F C Breedveld; J M Dayer
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

9.  Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis.

Authors:  Jun Shi; Steven J Kovacs; Yaning Wang; Thomas M Ludden; Vijay O Bhargava
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

10.  When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?

Authors:  M Dougados; P Emery; E M Lemmel; C A F Zerbini; S Brin; P van Riel
Journal:  Ann Rheum Dis       Date:  2004-07-22       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.